Better Recognition Needed for Early Diagnosis of hTTP
More recognition of hereditary thrombotic thrombocytopenic purpura (hTTP) is needed for patients to receive timely care, according to findings presented at ...
Racial and Socioeconomic Disparities Persist in U.S.-Based PE Care and Outcomes
Several racial and socioeconomic inequities continue to drive disparities in care and outcomes among patients with pulmonary embolism (PE) in the U.S. ...
Dalteparin to Apixaban for Upper Extremity DVT in Patients With Cancer
Dalteparin followed by apixaban was effective for treating deep vein thrombosis (DVT) and preserving central venous catheter (CVC) function in patients with cancer ...
Five-Year Follow-Up of Ruxolitinib Trial Shows Durable Clinical Results in PV Without Splenomegaly
Five-year results from the RESPONSE-2 study support the use of ruxolitinib as a second-line therapy for patients with inadequately controlled polycythemia vera (PV) without splenomegaly....
DOAC Clinics Benefit Patients and Referring Physicians
Since their introduction in 2010, direct oral anticoagulants (DOACS) have been an increasingly used therapy for patients who require anticoagulation. DOACs have advantages over warfarin ...
Rivaroxaban Possible Alternative to Heparin for VTE Prophylaxis After Laparoscopic Surgery for Colorectal Cancer
Use of rivaroxaban was superior to placebo for the extended prevention of venous thromboembolism (VTE) in patients after they underwent laparoscopic surgery for colorectal cancer, according to results from the PROLAPS-II study....
Anti-Coagulation Therapy Compliance Poor in Cancer-Associated VTE
Patients with cancer-associated venous thromboembolism (VTE) remain on anti-coagulation therapy for a short duration, but direct oral anticoagulants (DOACs) and warfarin may result in better compliance than low-molecular-weight heparin (LMWH) in these patients. ...
Rusfertide Therapy for Polycythemia Vera Leads to Sustained Hematocrit Control
Among patients with phlebotomy-dependent polycythemia vera (PV), treatment with rusfertide, a hepcidin mimetic administered weekly as a subcutaneous injection, continues to be effective, results in sustained hematocrit control, and ...
Continuation Trial Confirms Symptom Reduction With Ropeginterferon Alfa-2b Therapy for PV
Researchers confirmed ropeginterferon alfa-2b’s power to effectively reduce symptoms in patients with polycythemia vera (PV), according to study results presented by Heinz Gisslinger, MD, at the EHA 2022 Congress....
Rivaroxaban Led to Low Rates of Major Bleeding in Non-Cirrhotic Splanchnic Vein Thrombosis, May Offer Alternative to Anticoagulation
Study results suggest the oral direct factor Xa inhibitor could serve as an alternative to standard anticoagulation for the management of this manifestation of unusual site venous thromboembolism (VTE)....
